Provided by Tiger Fintech (Singapore) Pte. Ltd.

COMPASS Pathways plc

3.65
+0.26507.84%
Volume:1.57M
Turnover:5.56M
Market Cap:337.79M
PE:-1.59
High:3.66
Open:3.42
Low:3.40
Close:3.38
Loading ...

Compass Pathways Announces Dosing Complete for All Participants in Part A of Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression

Business Wire
·
Yesterday

Compass Pathways completes dosing in Part A of Phase 3 psilocybin trial

TIPRANKS
·
Yesterday

BRIEF-Compass Pathways Announces Dosing Complete For All Participants In Part A Of Phase 3 Comp005 Trial Of Comp360 Psilocybin

Reuters
·
Yesterday

Compass Pathways Announces Dosing Complete for All Participants in Part a of Phase 3 Comp005 Trial of Comp360 Psilocybin for Treatment-Resistant Depression

THOMSON REUTERS
·
Yesterday

Compass Pathways Plc - Top-Line 6-Week Primary Endpoint Results Expected in Late June

THOMSON REUTERS
·
Yesterday

BUZZ-U.S. STOCKS ON THE MOVE-Dow, Nike, Coty

Reuters
·
16 Apr

BUZZ-Jefferies says J&J's depression drug sales bode well for psychedelics

Reuters
·
15 Apr

BRIEF-Compass Pathways Announces Completion Of Recruitment For The Phase 3 COMP005 Trial Of COMP360 Psilocybin For Treatment-Resistant Depression

Reuters
·
26 Mar

Compass Pathways Announces Completion of Recruitment for the Phase 3 Comp005 Trial of Comp360 Psilocybin for Treatment-Resistant Depression

THOMSON REUTERS
·
26 Mar

Compass Pathways Plc - Comp006 26-Week Data Expected in Second Half of 2026

THOMSON REUTERS
·
26 Mar

Compass Pathways Plc: on Track for Top-Line 6-Week Primary Endpoint Results in Late Q2

THOMSON REUTERS
·
26 Mar

Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression

Business Wire
·
26 Mar

Psychedelic: Exclusive talk with biotech company Clearmind Medicine

TipRanks
·
22 Mar

Compass Pathways announces published study on psilocybin in depression

TIPRANKS
·
18 Mar

Compass Pathways Plc - Study's Findings Suggest 25 Mg Comp360 Psilocybin Shows Longer Maintenance of Antidepressant Effects

THOMSON REUTERS
·
18 Mar

Compass Pathways Plc - Comp360 Generally Well Tolerated With Three Reported Tesaes

THOMSON REUTERS
·
18 Mar

Compass Pathways Plc: Top-Line 6-Week Comp005 Data Is Expected in Q2 2025

THOMSON REUTERS
·
18 Mar

Compass Pathways Announces Publication of Results From Comp004 Study on Comp360 Psilocybin for Treatment-Resistant Depression

THOMSON REUTERS
·
18 Mar

Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial

TipRanks
·
14 Mar

Compass Pathways to Participate in Stifel Virtual CNS Forum

Business Wire
·
11 Mar